Quankai Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Quankai Cheng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Haicheng Zhong
Affiliation Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
2 shared publications- Jie Deng
Department of Cardiology, The Second Affiliated Hospital of Xi’an Jiao tong University, Xi’an, China
2 shared publications Jingjing Sun
Affiliation Department of Cardiology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
2 shared publicationsChang Liu
Affiliation Department of Cardiology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
1 shared publication- Chang Liu
School of Computer Science, Wuhan University, Wuhan, China
1 shared publication Sheng Zhou
Affiliation Department of Cardiology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
1 shared publication
Latest Publications
- Open Access
- 24 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325949
Comparison of systemic immunoinflammatory biomarkers for assessing severe abdominal aortic calcification among US adults aged≥40 years: A cross-sectional analysis from NHANES
Objective: Several novel biomarkers, including the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), and monocyte-lymphocyte ratio (MLR), are linked to the systemic immunity inflammation response and the odds and severity of abdominal aortic calcification (AAC). However, still no previous research has systematically compared their association with severe AAC. Methods: This study utilized a cross-sectional approach, examining a cohort of 3,047 adults from National Health and Nutrition Examination Survey (NHANES). Weighted logistic regression was utilized to investigate the associations between a range of immunoinflammatory biomarkers and the likelihood of severe AAC. Segmented regression and limited cubic spline models were used in the investigation to characterize the threshold effects and non-linear correlations. Additionally, subgroup and interaction tests, Spearman correlation, least absolute shrinkage, and selection operator regression studies were conducted. Results: The 3047 participants included in this study had a mean age of 58.63 years and 51.79% were female. After fully adjusting for all covariates, the ln-SIRI (OR 1.39 [CI 1.10–1.74], P = 0.005), ln-AISI (OR 1.26 [1.03–1.53], P = 0.024), and ln-MLR (OR 1.62 [1.15–2.30], P = 0.006) were significantly correlated with the odds of severe AAC. A non-linear dose-response relationship was observed between ln-SII and severe AAC. Additional subgroup analyses revealed that this relationship was more evident in the diabetic population. Additionally, MLR (AUC = 0.644) predicted the prevalence of severe AAC better than other biomarkers, and the prediction model constructed in conjunction with screened clinical indicators showed good predictive value (AUC = 0.853). Conclusions: In this study, we comprehensively evaluated and compared the associations between six biomarkers and severe AAC, and developed a clinical prediction model using the MLR with the best predictive effect. However, cohort studies and model validation are still needed in the future to further confirm their relationship.
- 24 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325949
Open AccessComparison of systemic immunoinflammatory biomarkers for assessing severe abdominal aortic calcification among US adults aged≥40 years: A cross-sectional analysis from NHANES
Objective: Several novel biomarkers, including the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), and monocyte-lymphocyte ratio (MLR), are linked to the systemic immunity inflammation response and the odds and severity of abdominal aortic calcification (AAC). However, still no previous research has systematically compared their association with severe AAC. Methods: This study utilized a cross-sectional approach, examining a cohort of 3,047 adults from National Health and Nutrition Examination Survey (NHANES). Weighted logistic regression was utilized to investigate the associations between a range of immunoinflammatory biomarkers and the likelihood of severe AAC. Segmented regression and limited cubic spline models were used in the investigation to characterize the threshold effects and non-linear correlations. Additionally, subgroup and interaction tests, Spearman correlation, least absolute shrinkage, and selection operator regression studies were conducted. Results: The 3047 participants included in this study had a mean age of 58.63 years and 51.79% were female. After fully adjusting for all covariates, the ln-SIRI (OR 1.39 [CI 1.10–1.74], P = 0.005), ln-AISI (OR 1.26 [1.03–1.53], P = 0.024), and ln-MLR (OR 1.62 [1.15–2.30], P = 0.006) were significantly correlated with the odds of severe AAC. A non-linear dose-response relationship was observed between ln-SII and severe AAC. Additional subgroup analyses revealed that this relationship was more evident in the diabetic population. Additionally, MLR (AUC = 0.644) predicted the prevalence of severe AAC better than other biomarkers, and the prediction model constructed in conjunction with screened clinical indicators showed good predictive value (AUC = 0.853). Conclusions: In this study, we comprehensively evaluated and compared the associations between six biomarkers and severe AAC, and developed a clinical prediction model using the MLR with the best predictive effect. However, cohort studies and model validation are still needed in the future to further confirm their relationship.
- Open Access
- 17 May 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1393333
Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis
Background: Cardiovascular disease (CVD) poses a significant global health and economic challenge, with atherosclerosis being a primary cause. Over the past 40 years, substantial research has been conducted into the prevention and reversal of atherosclerosis, resulting in the development of lipid-lowering agents such as statins and fibrates. Despite the extensive literature and formulation of numerous therapeutic guidelines in this domain, a comprehensive bibliometric analysis of the current research landscape and trends has not been performed. This study aimed to elucidate the evolution and milestones of research into lipid-lowering treatments for coronary heart disease (CHD) in conjunction with hyperlipidemia through bibliometric analysis, offering insights into future directions for treatment strategies.Methods: This study examined publications from 1986 to 2023 retrieved from the Web of Science database (Core Collection). Utilizing tools such as VOSviewer, Pajek, and CiteSpace, we analyzed publication and citation numbers, H-indexes, contributions by countries and institutions, authorship, journal sources, and keyword usage to uncover research trajectories and areas of focus.Results: Our analysis of 587 publications revealed a recent surge in research output, particularly post-2003. The American Journal of Cardiology published the highest number of studies, with 40 articles, whereas Circulation received the highest number of citations (6,266). Key contributors included the United States, Japan, and China, with the United States leading in citation numbers and the H-index. Harvard University and Leiden University emerged as pivotal institutions, and Professors J. Wouter Jukema and Robert P. Giugliano were identified as leading experts. Keyword analysis disclosed five thematic clusters, indicating a shift in research towards new drug combinations and strategies, signaling future research directions.Conclusion: The last 4 decades have seen a notable rise in publications on lipid-lowering therapies for CHD and hyperlipidemia, with the United States retaining world-leading status. The increase in international collaboration aids the shift towards research into innovative lipid-lowering agents and therapeutic approaches. PCSK9 inhibitors and innovative combination therapies, including antisense oligonucleotides and angiopoietin-like protein 3 inhibitors, provide avenues for future research, intending to maximize the safety and efficacy of treatment approaches.
- 17 May 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1393333
Open AccessResearch trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis
Background: Cardiovascular disease (CVD) poses a significant global health and economic challenge, with atherosclerosis being a primary cause. Over the past 40 years, substantial research has been conducted into the prevention and reversal of atherosclerosis, resulting in the development of lipid-lowering agents such as statins and fibrates. Despite the extensive literature and formulation of numerous therapeutic guidelines in this domain, a comprehensive bibliometric analysis of the current research landscape and trends has not been performed. This study aimed to elucidate the evolution and milestones of research into lipid-lowering treatments for coronary heart disease (CHD) in conjunction with hyperlipidemia through bibliometric analysis, offering insights into future directions for treatment strategies.Methods: This study examined publications from 1986 to 2023 retrieved from the Web of Science database (Core Collection). Utilizing tools such as VOSviewer, Pajek, and CiteSpace, we analyzed publication and citation numbers, H-indexes, contributions by countries and institutions, authorship, journal sources, and keyword usage to uncover research trajectories and areas of focus.Results: Our analysis of 587 publications revealed a recent surge in research output, particularly post-2003. The American Journal of Cardiology published the highest number of studies, with 40 articles, whereas Circulation received the highest number of citations (6,266). Key contributors included the United States, Japan, and China, with the United States leading in citation numbers and the H-index. Harvard University and Leiden University emerged as pivotal institutions, and Professors J. Wouter Jukema and Robert P. Giugliano were identified as leading experts. Keyword analysis disclosed five thematic clusters, indicating a shift in research towards new drug combinations and strategies, signaling future research directions.Conclusion: The last 4 decades have seen a notable rise in publications on lipid-lowering therapies for CHD and hyperlipidemia, with the United States retaining world-leading status. The increase in international collaboration aids the shift towards research into innovative lipid-lowering agents and therapeutic approaches. PCSK9 inhibitors and innovative combination therapies, including antisense oligonucleotides and angiopoietin-like protein 3 inhibitors, provide avenues for future research, intending to maximize the safety and efficacy of treatment approaches.